Antinociceptive interactions between mu-opioid receptor agonists and the serotonin uptake inhibitor clomipramine in rhesus monkeys: role of mu agonist efficacy

Matthew L. Banks, Kenner C. Rice, S. Stevens Negus

Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA, USA (MLB, SSN)

Chemical Biology Research Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, DHHS, Bethesda, MD, USA (KCR)
Running Title: Mu agonist and clomipramine interactions

Corresponding Author: S. Stevens Negus

Department of Pharmacology and Toxicology
Virginia Commonwealth University
410 North 12th Street
PO Box 980613
Richmond, VA 23298
Phone: (804) 828-3158
FAX: (804) 828-2117
email: ssnegus@vcu.edu

Number of text pages: 34
Number of Tables: 2
Number of Figures: 4
Number of References: 40

Abstract: 240
Introduction: 563 (excluding references)
Discussion: 1500 (excluding references)
Recommend Section: Behavioral Pharmacology

Non-standard abbreviations: rostroventral medulla (RVM); percent maximum possible effect (%MPE); analysis of variance (ANOVA)
ABSTRACT:

Mu-opioid agonists are effective analgesics but have undesirable effects such as sedation and abuse liability that limit their clinical effectiveness. Serotonergic systems also modulate nociception, and serotonin uptake inhibitors may be useful as adjuncts to enhance analgesic effects and/or attenuate undesirable effects of mu agonists. This study examined effects of the serotonin uptake inhibitor clomipramine on behavioral effects produced in rhesus monkeys by mu agonists with varying efficacy at mu receptors (nalbuphine > morphine > methadone). Clomipramine and each mu agonist were studied alone and in fixed-proportion mixtures in assays of schedule-controlled responding, thermal nociception and capsaicin-induced thermal allodynia. In the assay of schedule-controlled responding, all mu agonists dose-dependently decreased response rates. Clomipramine was inactive alone and did not alter effects of mu agonists. In the assay of thermal nociception, all mu agonists produced dose-dependent antinociception. Clomipramine was inactive alone but produced a proportion-dependent enhancement of the antinociceptive effects of nalbuphine > morphine > methadone. In the assay of capsaicin-induced allodynia, nalbuphine produced dose-dependent anti-allodynia. Clomipramine alone was inactive, but as in the assay of thermal nociception, it produced a proportion-dependent enhancement in the effects of nalbuphine. These findings suggest that serotonin uptake inhibitors can selectively enhance the antinociceptive effects of mu agonists in nonhuman primates. These effects of serotonin uptake inhibitors may be dependent on the proportion of the serotonin uptake inhibitor and the efficacy of the mu agonist. The greatest enhancement was observed with intermediate proportions of clomipramine in combination with the low-efficacy mu agonist nalbuphine.
INTRODUCTION:

Mu-opioid agonists are commonly used in the treatment of pain. Although mu agonists are effective analgesics, they also have undesirable effects such as sedation and abuse liability that limit their clinical utility. In the development of analgesics with improved therapeutic profiles, one strategy has been to combine mu agonists with other compounds targeting other biological receptor systems to selectively enhance the antinociceptive effects and/or attenuate undesirable effects (Dietis et al., 2009). Toward this end, the serotonin system might be one possible biological target of interest.

Nociception is modulated by multisynaptic descending pathways that include both opioidergic and serotonergic mechanisms (Basbaum and Fields, 1984). Opioids can act directly at the spinal dorsal horn to block nociceptive transmission by primary afferent nociceptors or indirectly at supra-spinal levels to inhibit GABAergic inputs and thereby modulate rostroventral medulla (RVM) OFF and ON cells and produce a net descending inhibition of nociceptive transmission (Fields et al., 2006). Serotonergic descending neurons also originating in the RVM tonically release serotonin in the spinal dorsal horn and may influence nociceptive input by amplifying the impact of other descending inhibitory systems (Fields et al., 2006). Moreover, there appears to be a descending serotonergic facilitatory nociceptive pathway originating in the brainstem and targeting 5-HT3 receptors in the dorsal horn (Suzuki et al., 2002; Rahman et al., 2004; Bannister et al., 2009). Overall, these results suggest that serotonin may play a role in the detection of noxious stimuli and that pharmacological modulation of this serotonergic system might be a biological target of therapeutic value.

In agreement with this possibility, previous studies have shown that drugs inhibiting serotonin uptake may enhance the antinociceptive effects of mu agonists. For example, we
reported that pretreatment with a single fixed dose of the serotonin uptake inhibitor clomipramine (0.1 mg/kg) enhanced the antinociceptive effects of mu agonists in nonhuman primates. The effects of clomipramine were dependent upon the efficacy of the mu agonist, with greater enhancement of low-efficacy agonists (Gatch et al., 1998). Moreover, this enhanced antinociceptive effect was replicated with the selective serotonin uptake inhibitor fluoxetine, but not with dopamine or norepinephrine transporter inhibitors, suggesting that the effect depended upon serotonin transporter inhibition (Gatch et al., 1998). Clomipramine has also been shown to enhance the antinociceptive effects of morphine in rodents (Kellstein et al., 1984; Ansuategui et al., 1989; Sierralta et al., 1995). Overall, these studies suggest further research on mu agonist and serotonin uptake inhibitor drug mixtures as candidate analgesics is warranted.

The aim of the present study was to confirm our previous finding of clomipramine enhancement of mu agonist antinociception and to extend these findings in three ways. First, our previous study examined effects of a single clomipramine dose administered as a pretreatment to multiple mu agonist doses. However, drug interactions can also be profitably studied using fixed-proportions drug mixtures (Tallarida, 2000; Stevenson et al., 2003; Negus et al., 2008; Negus et al., 2009), and clinically available drug-combination products typically exist as fixed-proportion mixtures. Therefore, the present study examined effects of clomipramine administered in fixed proportions with the low-efficacy mu agonist nalbuphine, the moderate-efficacy mu agonist morphine and the high-efficacy mu agonist methadone. Second, the selectivity of clomipramine-mu agonist interactions for antinociception vs. other effects is unknown. Insofar as motor impairment and nonspecific behavioral suppression may confound measures of thermal nociception, we therefore determined clomipramine-mu agonist interactions in an assay of schedule-controlled responding for comparison with antinociceptive interactions.
(Stevenson et al., 2003; Negus et al., 2008; Negus et al., 2009). Finally, to assess the generality of antinociceptive interactions to a model of inflammatory pain, clomipramine-nalbuphine interactions were also examined in an assay of capsaicin-induced thermal allodynia (Negus et al., 1993; Butelman et al., 2004; Do Carmo et al., 2008). We hypothesized that clomipramine would selectively enhance the antinociceptive and antiallodynic effects of mu agonists. Confirmation of our hypothesis would support further development of mu-opioid agonist and serotonin uptake inhibitor mixtures as candidate analgesics.
METHODS:

Subjects

A total of ten monkeys served as subjects. Three adult male rhesus monkeys (Macaca mulatta) were used in studies of schedule-controlled responding, four monkeys (two female and two male) were used in studies of thermal nociception, and three male monkeys were used in studies of capsaicin-induced thermal allodynia. Subjects weighed 4.5 to 12 kg during the course of these studies, and all monkeys had prior exposure to drugs (primarily dopaminergic and opioid compounds) and to the behavioral procedures in which they were tested. The subjects were individually housed, and water was freely available. Their diet consisted of Lab Diet monkey chow (Purina, Framingham, MA). This diet was supplemented with fresh fruit twice daily. In addition, monkeys in the assay of schedule-controlled behavior could earn additional food pellets during experimental sessions. A 12-h light/12-h dark cycle was in effect (lights on from 7:00 AM to 7:00 PM).

Animal maintenance and research were conducted in accordance with the guidelines provided by the National Institutes of Health Committee on Laboratory Animal Resources. The facility was licensed by the United States Department of Agriculture and the Association for Assessment and Accreditation of Laboratory Animal Care, and protocols were approved by the Institutional Animal Care and Use Committee. The health of the monkeys was monitored daily by technical staff and periodically by a veterinarian. Monkeys had visual, auditory, and olfactory contact with other monkeys throughout the study. Monkeys also had access to puzzle feeders, mirrors, and chew toys to provide environmental enrichment. Music or movies were played daily in the housing room.
Behavioral Procedures

Assay of schedule-controlled responding: Experiments were conducted in each monkey's home cage (dimensions 60 x 65 x 75 cm) as described previously (Stevenson et al., 2003; Negus et al., 2008; Negus et al., 2009). Each cage was modified to include an operant response panel (28 x 28 cm) mounted on the front wall. Three square translucent response keys (5.1 cm in diameter) were arranged 2.5 cm apart in a horizontal row 3.2 cm from the top of the operant panel. Each key could be transilluminated by red, green, or yellow stimulus lights. The operant panel also supported an externally mounted pellet dispenser (Med Associates, St. Albans, VT) that delivered 1-g banana-flavored food pellets (Test Diets, Richmond, IL) to a food receptacle mounted on the cage beneath the operant response panel. The panel was controlled by a MED-PC interface and an IBM compatible computer programmed in MEDSTATE Notation (MED Associates).

Experimental sessions were 75 min in duration and consisted of five 15-min cycles. Each cycle consisted of two components: a 10-min time-out period followed by a 5-min response period. During the time-out period, no stimulus lights were illuminated, and responding had no scheduled consequences. During the response period, the center key was transilluminated yellow, and the subjects could respond for up to 10 food pellets under a fixed-ratio 30 (FR30) schedule of reinforcement. If all 10 food pellets were earned before 5 min had elapsed, the lights were turned off, and responding had no scheduled consequences for the remainder of that response period. All monkeys were trained until they responded at rates greater than 1.0 response/s during all five cycles for 10 consecutive days, and we have shown previously that monkeys respond at relatively stable rates across successive response periods in this procedure (Stevenson et al., 2003; Negus et al., 2008; Negus et al., 2009).
Sessions were conducted 5 days a week. Test sessions were usually conducted on Tuesdays and Fridays, and training sessions were conducted on Mondays, Wednesdays, and Thursdays. In addition, test sessions were conducted only after a training session during which the monkeys responded at rates greater than 1.0 response/s for all five cycles. During training sessions, monkeys received either no injection or saline injections at the beginning of each cycle. During test sessions, test compounds were administered using a cumulative dosing procedure, in which doses of the test drug or drug mixture were administered at the beginning of each cycle, and each dose increased the total cumulative dose by one-fourth or one-half log units.

Initially, dose-effect curves were determined for nalbuphine (0.032 – 3.2 mg/kg), morphine (0.032 – 3.2 mg/kg), methadone (0.1 – 5.6 mg/kg), and clomipramine (0.1 – 10 mg/kg) alone, and each drug was tested twice. Mu agonists were tested up to doses that eliminated responding. Higher clomipramine doses were not tested to minimize risk of potential untoward effects such as convulsions (Pisani et al., 2002). Subsequently, three mixtures of clomipramine in combination with each mu agonist were examined. Because clomipramine was inactive in this or the other procedures used in this study, the relative potency of clomipramine to the mu agonists could not be used to adjust clomipramine dose in accordance with procedures for dose-addition analysis (e.g. Stevenson et al., 2003; Negus et al., 2008; Negus et al., 2009). Consequently, the clomipramine proportions were initially calibrated to methadone, the least potent of the mu agonists studied. Thus, clomipramine/methadone mixtures were studied across a range of three proportions (0.33: 1, 1:1 and 3:1 clomipramine/methadone) such that the intermediate proportion was 1:1 clomipramine/methadone, and three-fold lower and higher proportions were also studied. Proportions of clomipramine with the other mu agonists were then adjusted according to the relative potency of those drugs in comparison to methadone.
Thus, morphine was 1.6-fold more potent than methadone, and clomipramine proportions were increased by a factor of 1.6 (0.53:1, 1.6:1 and 4.8:1 clomipramine/morphine). Similarly, nalbuphine was 5.2-fold more potent than methadone, and clomipramine proportions were increased by a factor of 5.2 (1.7:1, 5.2:1, and 15.6:1). In this way, a constant relationship was maintained between the proportion of clomipramine and the relative potency of the mu agonist in the assay of schedule-controlled responding. Each mixture was tested once, and one week separated each test. Nalbuphine, morphine, methadone, and all mixtures were tested up to doses that eliminated responding in most or all monkeys.

Assay of thermal nociception: Monkeys were seated in acrylic restraint chairs so that their tails hung down freely. The bottom 10 cm of each monkey’s shaved tail was immersed in a thermal container of warm water. If the subject did not remove its tail within 20 s, the experimenter removed the tail, and a latency of 20 s was assigned to that measurement. During each cycle of measurements, tail-withdrawal latencies were measured from water heated to 38, 50 and 54°C. The order in which the temperatures were presented varied from one set of measurements to the next. Experiments were conducted no more than twice a week. A stopwatch was used to measure and record time intervals.

Each test session consisted of multiple 15-min cycles. Before the first drug dose was administered, baseline latencies to tail-withdrawal at 38, 50 and 54°C water were determined. Testing continued only if tail withdrawal from 38°C water did not occur before the 20 s cutoff, and if tail withdrawal occurred in ≤ 2 s from 50 and 54°C water. This criterion was met during every session with every monkey in this study. During cumulative dosing experiments, a single drug dose was administered at the start of each of five sequential 15 min cycles, and each dose
increased the total cumulative dose by one-fourth or one-half log units. Starting 10 min after each injection, tail-withdrawal latencies were recorded as described above. Initially, complete dose-effect curves were determined for nalbuphine (0.32 – 3.2 mg/kg, one monkey tested with 10 mg/kg), morphine (0.1 – 5.6 mg/kg), methadone (0.1 – 5.6 mg/kg) and clomipramine (0.1 – 5.6 mg/kg) alone. Mu agonists were tested up to doses produced maximal antinociception using the 50°C thermal stimulus, and clomipramine doses were limited as discussed above. Subsequently, three mixtures of each mu agonist in combination with clomipramine were examined, and the proportions of each drug in the mixtures were identical to those examined in the assay of schedule-controlled responding described above. Each drug mixture was tested once.

The time courses of saline and selected doses of nalbuphine (1.0 mg/kg), morphine (3.2 mg/kg), methadone (3.2 mg/kg) and clomipramine (10 mg/kg) were also examined in the assay of thermal nociception using a stimulus intensity of 50°C. For these studies, baseline tail withdrawal latencies from 50°C water were determined before drug treatment and 3, 10, 17, 30, 56, 100 and 300 min after drug treatment.

**Assay of capsaicin-induced thermal allodynia:** Monkeys were seated in acrylic restraint chairs as described above. The base of each monkey’s tail was shaved, and baseline tail-withdrawal latencies were measured from water heated to 38, 42, 46, and 50°C. Temperatures were presented in random order. If the subject did not withdraw its tail within 20 s, the experimenter removed the tail, and a latency of 20 s was assigned for that measurement. Using this procedure, temperature-effect curves were determined in each monkey at the beginning of each session, and the highest temperature that failed to elicit tail withdrawal was determined (i.e., the highest temperature to produce a tail-withdrawal latency of 20 s). Water heated to this
temperature then served as the thermal stimulus for subsequent studies of allodynia during that session. Allodynia was elicited by topical application of capsaicin as described previously (Butelman et al., 2004; Do Carmo et al., 2008). After baseline tail-withdrawal latency determinations, the tail of each subject was degreased with an alcohol pad. A topical capsaicin patch was prepared as described below (see Drugs), and the patch was applied to a region ~ 5cm from the bottom of the tail for 5 min. After 5 min, the patch was removed and tail-withdrawal latencies were redetermined using the thermal stimulus identified from the baseline temperature-effect curve. Initially, nalbuphine (0.032 – 1.0 mg/kg) and clomipramine (1.0 – 10 mg/kg) were tested alone. Subsequently, three mixtures of nalbuphine in combination with clomipramine were examined, and the proportions of each drug in the mixtures were identical to those examined in the assay of schedule-controlled responding described above. Tests were conducted no more than twice per week.

Data analysis:

For the assay of schedule-controlled responding, raw response rates from each test cycle were converted to percent of control using the average rate from the previous training day in that monkey as the control value. For the assay of thermal nociception, raw tail withdrawal latencies were expressed as Percent Maximum Possible Effect (%MPE) using the equation %MPE = [(Test Latency – Baseline Latency)/(20 – Baseline Latency)]*100, where "test latency" was the tail withdrawal latency obtained after drug administration, "baseline latency" was the latency obtained at that temperature at the beginning of the session prior to drug administration and "20" was the cutoff latency in sec. For the assay of capsaicin-induced thermal allodynia, raw tail withdrawal latencies obtained 15, 30, 45 and 60 min after removal of the capsaicin patch were
converted to %MPE using the equation %MPE=\[(\text{Test Latency}-\text{Capsaicin Alone Latency})/(20-\text{Capsaicin Alone Latency})\]*100, where "test latency" was the tail withdrawal latency obtained at each time point after drug pretreatment + capsaicin patch treatment, "Capsaicin Alone Latency" was the latency obtained at the corresponding time point after treatment with the capsaicin patch alone, and "20" was the cutoff latency in sec. Data from all four time points after capsaicin patch removal were then averaged to yield a mean±SEM %MPE for each monkey during each session.

Data for each mu agonist alone and in combination with different proportions of clomipramine were analyzed using a two-way repeated-measures ANOVA with mu agonist dose and clomipramine proportion as the main factors. In the presence of a significant main effect, post-hoc analysis was conducted using the Bonferroni t-test method for planned comparisons between each drug mixture and the mu agonist alone. In addition, ED50 values were determined for each mu agonist alone and in combination with clomipramine in each monkey. ED50 values were calculated by interpolation when only two data points were available (one below and one above 50% effect) or by linear regression when at least three data points were available on the linear portion of the dose-effect curve. Individual ED50 values were averaged to yield mean ED50s and 95% confidence limits. Significance was established a priori at the 95% confidence level.

To evaluate drug interactions across assays, the relative potency of each mu agonist and drug mixture to produce rate suppression vs. antinociception was quantified using dose-ratio analysis as described previously (Banks et al., 2010; Negus et al., 2008; Negus et al., 2009). Specifically, dose-ratios (DR) for each mu agonist or drug mixture were calculated as the ratio of the ED50 in the assay of schedule-controlled responding / ED50 in the assay of thermal nociception (50 and 54°C). Thus, if a drug or drug mixture was equipotent in the two procedures,
then ED50 in the assay of schedule-controlled responding would be equal to the ED50 in the assay of thermal nociception, and DR=1. A DR >1 indicates that the drug or drug mixture was more potent in the assay of thermal nociception. Conversely, DR <1 indicates that the drug or drug mixture was more potent in the assay of schedule-controlled responding. For nalbuphine administered alone or in combination with clomipramine, dose-ratios were also calculated for rate suppression vs. antiallodynia as ED50 in the assay of schedule-controlled responding / ED50 in assay of capsaicin-induced thermal alldynia. The potency of each drug or drug mixture was considered to be different across procedures if the 95% confidence limits of the ED50 values in the procedures did not overlap.

Time-course data in the assay of thermal nociception were analyzed by two-way repeated-measures analysis of variance, with drug (saline, clomipramine, nalbuphine morphine, methadone) as one factor and time after administration (3, 10, 17, 30, 56, 100 and 300 min) as the second factor. A significant analysis of variance was followed by the Bonferroni post-hoc test for multiple planned comparisons. The criterion for significance was set a priori at the 95% confidence level.

**Drugs:** Racemic methadone HCl and (−)-morphine sulfate were provided by the National Institute on Drug Abuse (Besthesda, MD). Nalbuphine HCl was generously provided by Dr. Kenner Rice (Chemical Biology Research Branch, National Institute on Drug Abuse and National Institute on Alcohol Abuse and Alcoholism). Clomipramine HCl was obtained from Sigma Aldrich (St. Louis, MO). Mu agonists and clomipramine were dissolved in sterile water for intramuscular injection in the thigh, and doses are expressed in terms of the salt forms listed above. Capsaicin (Sigma-Aldrich) was dissolved in a vehicle composed of 70% alcohol and
30% sterile water approximately 15 min before use, and it was delivered transdermally (topical patch). Specifically, the patch consisted of a 1-cm² piece of two-ply gauze affixed to adhesive backing (23-mm wide; Nexcare Bandages) and 12-cm long elastic tape (5-cm wide; Elastikon Tape) purchased from Henry Schein (Denver, PA). The 0.61 mg/mL capsaicin solution (0.3 mL) was slowly injected onto the patch. Within 30 s of preparing the capsaicin patch, it was secured to the monkey’s tail with the elastic tape and left on for 5 min.

RESULTS:

Assay of schedule-controlled responding: The average control response rate (± SEM) determined on the days preceding test days throughout the study, was 2.9 (±0.1) responses/s. Fig. 1 shows the dose-effect curves for nalbuphine (left panel), morphine (center panel), and methadone (right panel) administered alone. All of the mu agonists produced dose-dependent decreases in response rates, and the ED50 values are shown in Table 1. The serotonin uptake inhibitor clomipramine up to 10 mg/kg did not reliably alter response rates (data not shown) and an ED50 value could not be determined. Clomipramine maximally decreased rates of responding to 65.4 ± 18.3 % control (mean ± SEM) after 10 mg/kg, and higher doses were not tested to minimize the risk of toxicity (Pisani et al., 2002).

Fig. 1 also shows the dose-effect curves for nalbuphine (left), morphine (center), and methadone (right) administered in combination with different proportions of clomipramine. Clomipramine had little or no effect on the rate decreasing effects of mu agonists. Two-way analysis of variance (ANOVA) indicated significant main effects for dose of each mu agonist [nalbuphine (F(3,6) = 29.1), morphine (F(3,6) = 23.2), methadone (F(3,6) = 119.1), p <0.05], but no significant main effect of clomipramine proportion and no significant interaction between mu
agonist dose and clomipramine proportion. Table 1 shows that clomipramine did not significantly alter the ED50 value for any of the mu agonists to decrease rates of schedule-controlled responding.

**Assay of thermal nociception:** Under baseline conditions, monkeys never withdrew their tails from water heated to 38°C. The mean ± SEM tail withdrawal latency from 50°C water was 0.9 ± 0.1 s and from 54°C water was 0.8 ± 0.1 s. Fig. 2 shows the dose-effect curves for each mu agonist administered alone at the two thermal intensities (50°C and 54°C), and ED50 values are shown in Table 1. All three mu agonists produced dose-dependent antinociceptive effects at both stimulus intensities, but they differed in their potencies and maximal effects. Nalbuphine was the most potent compound. It increased %MPE above 50% in all monkeys at 50°C, but it increased %MPE above 50% in only two of four monkeys at 54°C. Morphine and methadone displayed similar potencies. Morphine increased %MPE above 50% in all monkeys at 50°C but in only three of four monkeys at 54°C. Methadone increased %MPE above 50% in all monkeys at both stimulus intensities. Clomipramine doses up to 5.6 mg/kg did not produce a significant antinociceptive effect (data not shown), and ED50 values could not be calculated. Clomipramine produced a maximum %MPE of 10.0 ± 5.7 and 0.14 ± 0.54 after 5.6 mg/kg at 50 and 54°C, respectively.

Fig. 2 also shows the dose-effect curves for nalbuphine (left panels), morphine (center panels), and methadone (right panels) administered alone and in combination with different proportions of clomipramine at 50°C (top panels) and 54°C (bottom panels). In general, clomipramine enhanced the antinociceptive effects of mu agonists, and the most reliable enhancement was observed with the low-efficacy mu agonist nalbuphine. Two-way ANOVA
for nalbuphine at the 50°C thermal intensity revealed significant main effects of nalbuphine dose (F(4,12)=36.3, p <0.05) and clomipramine proportion (F(3,9)=6.3, p <0.05), but no significant interaction. Post-hoc analysis revealed that at the 0.1 mg/kg (5.2:1 mixture) and 0.32 mg/kg (5.2:1 and 15.6:1 mixtures) nalbuphine doses, the clomipramine/nalbuphine mixtures produced greater antinociception than nalbuphine alone. For morphine or methadone at 50°C, there were significant main effects of morphine (F(4,12)=108.6, p <0.05) or methadone (F(4,12)=52.1, p <0.05) dose, but no significant main effects of clomipramine proportion and no interactions.

For nalbuphine at the 54°C thermal intensity, two-way ANOVA indicated significant main effects of nalbuphine dose (F(4,12)=18.1, p <0.05) and clomipramine proportion (F(3,9)=9.0, p <0.05) and a significant interaction (F(12,35)=2.5, p <0.05). Post-hoc analysis revealed that at the 1.0 mg/kg nalbuphine dose, the 15.6:1 clomipramine/nalbuphine mixture produced significantly greater antinociception than nalbuphine alone, and at the 3.2 mg/kg nalbuphine dose, all clomipramine/nalbuphine mixtures produced significantly greater antinociception than nalbuphine alone. For morphine at the 54°C thermal intensity, there were significant main effects of morphine dose (F(4,12)=42.9, p <0.05) and clomipramine proportion (F(3,9)=5.7, p <0.05) and a significant interaction (F(12,36)=3.2, p <0.05). Post-hoc analysis revealed that at the 3.2 mg/kg morphine dose, the 0.53:1 and 4.8:1 clomipramine/morphine mixtures produced significantly greater antinociception than morphine alone, and at the 5.6 mg/kg morphine dose, all clomipramine/morphine mixtures produced significantly greater antinociception than morphine alone. For methadone at 54°C, there was a significant main effect of methadone dose (F(4,12)=27.6, p <0.05), no significant main effect of clomipramine proportion and a significant interaction (F(12,36)=4.2, p <0.05). Post-hoc analysis revealed that
the 0.33:1 clomipramine/methadone mixture produced significantly greater antinociception than methadone alone at the 5.6 mg/kg dose.

Table 1 shows that clomipramine did not significantly alter mu agonist ED50 values for the monkeys in which ED50 values could be determined. However, consistent with the ANOVA results described above, clomipramine increased the proportion of monkeys in which ED50 values could be determined for both nalbuphine (50 and 54°C) and morphine (54°C). In contrast, high proportions of clomipramine decreased the proportion of monkeys in which ED50 values could be determined with methadone (54°C).

**Assay of capsaicin-induced thermal allodynia:** Because clomipramine was most effective in enhancing the antinociceptive effects of the low-efficacy mu agonist nalbuphine, a follow-up experiment evaluated effects of clomipramine on the antiallodynic effects of nalbuphine in an assay of capsaicin-induced thermal allodynia. In this procedure, the highest thermal stimulus that failed to elicit tail withdrawal before capsaicin treatment was 42°C in two monkeys and 46°C in one monkey throughout the study. Topical treatment with capsaicin alone produced allodynia as indicated by reduced tail withdrawal latencies at these temperatures to 2.1 ± 0.1 s, 2.3 ± 0.5 s, 3.8 ± 1.2 s and 5.6 ± 1.6 s at 15, 30, 45, and 60 min after capsaicin treatment, respectively.

Figure 3 shows the antiallodynic effects of nalbuphine administered alone or in combination with varying proportions of clomipramine, and ED50 values are shown in Table 1. Nalbuphine alone produced dose-dependent antiallodynia, whereas clomipramine alone was completely ineffective (maximum %MPE of -8.6 ± 6.2% at doses of 1.0-10 mg/kg; data not shown). However, clomipramine enhanced the antiallodynic effects of nalbuphine. Repeated-
measures two-way ANOVA demonstrated a significant main effect of nalbuphine dose (F(2,4)=124.2, p <0.05), no significant main effect of clomipramine proportion and a significant clomipramine proportion and nalbuphine dose interaction (F(6,12)=8.4, p <0.05). Post-hoc analysis revealed that at the 0.1 mg/kg nalbuphine dose, the 5.2:1 and 15.6:1 clomipramine/nalbuphine mixtures produced significantly greater antiallodynia than nalbuphine alone. Table 1 shows that the 5.2:1 clomipramine/nalbuphine mixture also significantly decreased the ED50 value for nalbuphine.

**Dose-ratio analysis**: Table 2 shows the effects of clomipramine on the relative potency of nalbuphine, morphine and methadone to produce rate suppression vs. thermal antinociception. Dose-ratios for each mu agonist alone or in combination with varying proportions of clomipramine were calculated as the ED50 in the assay of schedule-controlled responding / ED50 in the assay of thermal nociception at each stimulus intensity. Dose-ratios could not be calculated for clomipramine alone at either thermal intensity because of a lack of significant activity in the assay of thermal nociception in all subjects. A dose-ratio could also not be calculated for nalbuphine and morphine alone at 54°C. Clomipramine increased dose-ratios relative to nalbuphine alone at both 50 and 54°C, indicating that clomipramine/nalbuphine mixtures produced antinociception with less rate suppression than nalbuphine alone. Some clomipramine proportions also increased dose-ratios for morphine. However, clomipramine produced only a proportion-dependent decrease in the dose-ratios for methadone. In the assay of capsaicin-induced thermal allodynia, clomipramine in combination with nalbuphine in the 5.2:1 mixture also increased the dose-ratio compared to nalbuphine alone.
Time-course of clomipramine, nalbuphine, morphine, and methadone in the assay of thermal nociception: Figure 4 shows the time course of clomipramine (10 mg/kg), nalbuphine (1.0 mg/kg), morphine (3.2 mg/kg), and methadone (3.2 mg/kg) in the assay of thermal nociception at the 50°C thermal stimulus. All mu agonists produced a significant antinociceptive effect relative to saline treatment. Clomipramine did not produce a significant antinociceptive effect at any time point. Using duration of significant differences from saline treatment as a criterion, durations of action were nalbuphine < methadone < morphine.
DISCUSSION:

This study assessed interactions between the serotonin uptake inhibitor clomipramine and the low-efficacy mu agonist nalbuphine, the moderate-efficacy mu agonist morphine and the high-efficacy mu agonist methadone in assays of schedule-controlled responding, thermal nociception and capsaicin-induced thermal allodynia. The main findings support the hypothesis that serotonin uptake inhibitors can selectively enhance analgesia-related effects of low- to moderate-efficacy mu agonists. Mixtures of serotonin uptake inhibitors and low- to moderate-efficacy mu agonists may warrant further consideration and development as candidate analgesics.

Effects of clomipramine and mu agonists alone. In the present study, the mu agonists nalbuphine, morphine, and methadone all produced dose-dependent decreases in rates of schedule-controlled responding and increases in thermal antinociception consistent with previously published studies (Dykstra and Woods, 1986; Gerak et al., 1994; Gatch et al., 1995; Gatch et al., 1998; Stevenson et al., 2003). This is the first study to describe the antiallodynic effects of nalbuphine in nonhuman primates, although nalbuphine was shown to be effective in some rat models of inflammatory pain (Lomas et al., 2007; Ortiz et al., 2007; Ortiz and Castañeda-Hernández, 2008). Clomipramine produced little or no effect up to the highest dose tested in all three assays, and this agrees with previous studies in finding that clomipramine and other serotonin uptake inhibitors produce little effect on rates of schedule-controlled responding or thermal nociception in nonhuman primates (Kleven and Woolverton, 1993; Spealman, 1993; Gatch et al., 1998) or on pain-related behaviors in rodent models of inflammatory pain (Pedersen et al., 2005).
**Antinociceptive interactions between clomipramine and mu agonists.** Some proportions of clomipramine enhanced the antinociceptive effects of nalbuphine or morphine in the thermal nociception assay. These results are consistent with previous studies demonstrating clomipramine-induced enhancement of the antinociceptive effects of nalbuphine (Gatch et al., 1998) and morphine (Kellstein et al., 1984; Kellstein et al., 1988; Rosland et al., 1988; Ventafridda et al., 1990; Gatch et al., 1998). Furthermore, the relative inability of clomipramine to enhance antinociception produced by the high-efficacy mu agonist methadone agrees with our previous finding that clomipramine did not enhance the antinociceptive effects of the other high-efficacy mu agonist fentanyl (Gatch et al., 1998). Taken together, these results suggest that efficacy of the mu agonist at mu opioid receptors is one important determinant of antinociceptive interactions between serotonin uptake inhibitors and mu agonists. More specifically, serotonin uptake inhibition appears to be especially effective in enhancing the antinociceptive effects of relatively low-efficacy mu-opioid agonists.

A second important determinant of interactions between serotonin uptake inhibitors and mu agonists may be the proportion of the serotonin uptake inhibitor in the mixture, and in the present study, maximal enhancement of mu agonist antinociception was observed with low to intermediate clomipramine proportions. The highest proportion of clomipramine failed to produce further enhancement, and in the case of methadone, higher proportions of clomipramine actually attenuated methadone antinociception in some monkeys. These findings suggest a potential biphasic effect of clomipramine on mu agonist antinociception. The mechanisms that might limit or reverse clomipramine effects on mu agonist antinociception remain to be determined. One possibility is that serotonin uptake inhibitors increase serotonin levels at terminals of descending serotonergic neurons in the spinal dorsal horn (Sorkin et al., 1991;
Suzuki et al., 2004; Bannister et al., 2009), where low serotonin levels may selectively promote antinociceptive effects, and higher serotonin levels may also engage opposing, pronociceptive systems (Hylden and Wilcox, 1983; Oyama et al., 1996; Suzuki et al., 2002; Rahman et al., 2004). Other studies have also reported evidence for biphasic or opposing antinociceptive and pronociceptive effects of serotonin in the spinal cord; however, in contrast to the implications of the present study, some of these data have been interpreted to suggest that pronociceptive effects predominate at lower serotonin levels and that antinociception requires higher serotonin levels (Mason and Gao, 1998; Mason, 2001). Further research will be required to reconcile this apparent discrepancy.

Clomipramine was least effective in enhancing antinociceptive effects of methadone, and as noted above, this is consistent with a role for mu agonist efficacy as a determinant of clomipramine-mu agonist interactions. However, other factors may also contribute. For example, (−)-methadone inhibited synaptosomal serotonin uptake with a Ki of 14.1 nM, whereas (−)-morphine was inactive (Codd et al., 1995). Nalbuphine was not examined. Insofar as methadone's potency to block serotonin uptake is similar to its affinity for mu opioid receptors [e.g. 5.6±0.4 nM at human mu receptors; (Raynor et al., 1995)], methadone may already function as a mixed mu agonist/serotonin uptake inhibitor, and the addition of clomipramine may engage pronociceptive serotonergic systems more readily with methadone that with other opioids that lack activity at serotonin transporters.

The experimental design of the present study used fixed-proportion drug mixtures rather than fixed-dose pretreatments to evaluate clomipramine-mu agonist interactions. From a methodological perspective, this approach permits direct evaluation of drug combinations similar to the many fixed-proportion mixtures that are used clinically to treat pain (e.g. mu agonist-
acetaminophen preparations). Moreover, the use of fixed-proportion mixtures facilitates the application of dose-addition analysis to categorize and quantify interactions as synergistic, additive or subadditive (Tallarida, 2000). We have used this analysis previously to study interactions between mu agonists and other drugs (Stevenson et al., 2003; Negus et al., 2008). In the present study, dose-addition analysis turned out to be unnecessary, because clomipramine was inactive in all procedures, and when one drug in a mixture is inactive, dose-addition analysis reduces to a simple analysis of the degree to which the inactive drugs alters effects of the active drug. Thus, clomipramine-mu agonist interactions were synergistic, additive or subadditive to the degree that clomipramine significantly enhanced, failed to alter, or attenuated effects of the mu agonist.

**Selectivity of clomipramine-mu agonist interactions.** In contrast to clomipramine’s enhancement of the antinociceptive effects of nalbuphine>morphine>methadone, clomipramine had little or no effect on the rate-decreasing effects of any of the mu agonists in an assay of food-maintained, schedule-controlled responding. These findings suggest at least two conclusions. First, these findings suggest that clomipramine-induced enhancement of mu agonist antinociception did not result from a generalized depression of all behavior. Second, these findings suggest at least some degree of behavioral selectivity in the ability of clomipramine to enhance antinociceptive effects vs. other effects of mu agonists. This behavioral selectivity of clomipramine to enhance antinociceptive vs. rate-decreasing effects of mu agonists was reflected in clomipramine-induced changes in mu agonist dose-ratios to produce antinociception vs. rate-decreasing effects. Thus, some fixed-proportion mixtures of clomipramine and nalbuphine or morphine produced dose-ratios that were greater than the mu agonist alone. In contrast, clomipramine produced only proportion-dependent decreases in dose ratios for methadone.
Further research will be required to evaluate the degree to which clomipramine or other serotonin uptake inhibitors might alter other, potentially problematic effects of mu agonists such as respiratory depression, constipation or abuse-related effects.

**Antiallodynic interactions between clomipramine and nalbuphine.** The generality of analgesia-related interactions between clomipramine and nalbuphine was tested in the present study in a model of inflammatory pain. Nalbuphine was more potent in the assay of capsaicin-induced thermal allostodynia than in the assay of thermal nociception, which is consistent with previous results with morphine in this procedure (Do Carmo et al., 2008). As in the assay of thermal nociception, clomipramine enhanced the antiallodynic effects of nalbuphine, and peak levels of enhancement were achieved with the intermediate proportion of 5.2:1 clomipramine/nalbuphine. Thus, clomipramine interactions with analgesia-related effects of nalbuphine were similar in both procedures. These results agree with the finding that the serotonin uptake inhibitor fluoxetine enhanced effects of morphine in the formalin test in rats (Nayebi et al., 2001).

**Comparison to interactions between mu agonists and other drugs.** Results of the present study can be considered in the context of other studies conducted under identical conditions in our laboratory that have examined fixed-proportion drug mixtures of other drug classes in combinations with mu agonists. For example, like clomipramine, delta-opioid receptor agonists also produced a selective enhancement in the antinociceptive effects of mu agonists in rhesus monkeys (Stevenson et al., 2003; Negus et al., 2009). However, in contrast to the effects observed with clomipramine, delta agonist enhancement of mu agonist antinociception was not dependent upon the efficacy of the mu agonist. For example, the delta agonist SNC80 [(+)-4-[(\(\alpha\alpha\))-(2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl]-3-methoxybenzyl]-N,N-diethylbenzamide]
produced a robust enhancement of the antinociceptive effects of methadone. Previous studies have also examined interactions between the high-efficacy mu agonist fentanyl, and either the kappa-opioid agonist U-69,593 \([N\text{-methyl-2-phenyl-}N\text{-}(5R,7S,8S)-7-(pyrrolidin-1-yl)-1-oxaspiro[4.5]\text{dec-8-yl}]\text{acetamide}\) or the noncompetitive \(N\text{-Methyl-}\text{D-Aspartate glutamate receptor antagonist ketamine. U-69,593 produced only additive antinociceptive interactions in combination with fentanyl, but it tended to attenuate the rate-decreasing effects of fentanyl in the assay of schedule-controlled responding, and as a result, some U-69,593/fentanyl proportions displayed higher dose ratios for antinociception vs. rate suppression than fentanyl alone (Negus et al., 2008). Conversely, ketamine produced greater enhancement of the rate decreasing vs. antinociceptive effects of fentanyl, and as a result, ketamine produced only a proportion-dependent decrease in dose ratios for antinociception vs. rate suppression (Banks et al., 2010). Taken together, these studies illustrate the potential for a variety of different outcomes when mu agonists are combined with other drugs.

**Drug time course as a factor in drug interactions.** Drug interactions can be influenced by the time courses of drugs in a mixture, and differences in mu agonist/clomipramine interactions may have been influenced by the time courses rather than the efficacies of the mu agonists. However, the relative degrees of clomipramine enhancement (nalbuphine\textgreater morphine\textgreater methadone) did not correlate with either rate of onset (methadone\textgreater nalbuphine\textgreater morphine) or duration of action (morphine\textgreater methadone\textgreater nalbuphine) of approximately equi-analgesic mu agonist doses. Moreover, although clomipramine clearly enhanced antinociception induced by the rapid-onset, short-acting mu agonist nalbuphine, it did not enhance antinociceptive effects of similarly rapid-onset, short-acting mu agonist fentanyl, which has relatively high efficacy at mu receptors (Gatch et al., 1998). Taken together, these
results suggest that time course is less important than mu agonist efficacy as a determinant of interactions between mu agonists and serotonin uptake inhibitors.
ACKNOWLEDGEMENTS:

We appreciate the technical assistance of Ember Morrissey and Crystal Reynolds.
REFERENCES:


Ortiz MI and Castañeda-Hernández G (2008) Examination of the interaction between peripheral

Ortiz MI, Ponce-Monter H, Fernández-Martínez E, Perez-Hernández N, Macías A, Rangel-
acemetacin and opioids on the hargreaves model of thermal hyperalgesia. Pharmacol
Biochem Behav 88:47-54.


Pedersen L, Nielsen A, and Blackburn-Munro G (2005) Anti-nociception is selectively enhanced
by parallel inhibition of multiple subtypes of monoamine transporters in rat models of


mediated through rat spinal 5HT3 receptors is unaltered following carrageenan

Characterization of the cloned human mu opioid receptor. J Pharmacol Exp Ther
272:423-428.

Rosland JH, Hunskaar S, and Hole K (1988) Modification of the antinociceptive effect of
morphine by acute and chronic administration of clomipramine in mice. Pain 33:349-
355.


Footnotes:

This research was supported by National Institutes of Health grants [R01DA011460] and [T32DA007027]. A portion of this work was also supported by the Intramural Research Programs of the National Institute on Drug Abuse and the National Institute on Alcohol Abuse and Alcoholism.
Legends for Figures:

**Figure 1:** Effects of nalbuphine (left panel), morphine (center panel), and methadone (right panel) alone or in combination with different proportions of clomipramine in the assay of schedule-controlled responding. Abscissae: Dose of mu agonist alone or in the mixture in mg/kg (log scale). The corresponding dose of clomipramine depended upon the proportion of clomipramine in the mixture. Ordinates: Percent control rates of responding. Each point shows mean ± SEM for three monkeys.

**Figure 2:** Effects of nalbuphine (left panels), morphine (center panels), and methadone (right panels) alone or in combination with different proportions of clomipramine in the assay of thermal nociception at 50 (top panels) and 54°C (bottom panels). Abscissae: Dose of mu agonist alone or in the mixture in mg/kg (log scale). The corresponding dose of clomipramine depended upon the proportion of clomipramine in the mixture. Ordinates: Percent maximum possible effect (%MPE). Each point shows mean ± SEM for four monkeys. Open symbols represent significantly (p < 0.05) different from mu agonist alone within a given mu agonist dose. Note that one monkey was tested with a high dose of 10 mg/kg nalbuphine alone to achieve >50% MPE at 50°C, but because this was the only monkey tested at this dose, data from this test are excluded from the figure.

**Figure 3:** Effects of nalbuphine alone or in combination with different proportions of clomipramine in the assay of capsaicin-induced thermal allodynia. Abscissa: Dose of nalbuphine alone or in the mixture in mg/kg (log scale). The corresponding dose of clomipramine depended upon the proportion of clomipramine in the mixture. Ordinate: Percent maximum possible effect
Each point shows mean ± SEM for three monkeys. Open symbols represent significantly ($p < 0.05$) different from mu agonist alone within a given mu agonist dose.

**Figure 4:** Time course of antinociceptive effects from the low-efficacy mu agonist nalbuphine, the moderate-efficacy mu agonist morphine, the high-efficacy mu agonist methadone, the serotonin uptake inhibitor clomipramine, and saline administration in different groups of rhesus monkeys. Abscissa: Time (min) after administration. Ordinate: Percent maximum possible effect at the 50°C thermal intensity. Each point represents mean ± SEM of three rhesus monkeys. Two-way repeated-measures analysis of variance revealed a significant main effect of time $F(6,12) = 12.8$, $p < 0.05$, drug $F(4,8) = 39.1$, $p < 0.05$ and a significant time × drug interaction $F(24,48) = 9.2$, $p < 0.05$. Post-hoc analysis using the Bonferroni method for multiple planned comparisons demonstrated that nalbuphine and methadone were significantly different ($p < 0.05$) from vehicle at 3 min., and all mu agonists were significantly different from vehicle at 10 – 30 min. Nalbuphine’s effects returned to vehicle levels at 56 min and methadone’s at 300 min. Morphine’s effects were still significant at 300 min. Open symbols represent significantly ($p < 0.05$) different vehicle within a given time point.
Table 1: ED50 values in mg/kg (95% CL) for each mu-opioid agonist administered alone or in combination with varying proportions of clomipramine in assays of schedule-controlled responding (SCR), thermal nociception at 50 and 54°C and capsaicin-induced thermal allodynia.

<table>
<thead>
<tr>
<th>Treatment Condition</th>
<th>SCR ED50 (95% CL)</th>
<th>50°C ED50 (95% CL)</th>
<th>54°C ED50 (95% CL)</th>
<th>Thermal allodynia ED50 (95% CL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nalbuphine Alone</td>
<td>0.23 (0.06 – 0.91)</td>
<td>0.89 (0.23 – 3.40)</td>
<td>&gt;1.70&lt;sup&gt;α&lt;/sup&gt;</td>
<td>0.16 (0.09 – 0.29)</td>
</tr>
<tr>
<td>1.7:1 Clomip/Nalbuphine</td>
<td>0.10 (0.04 – 0.24)</td>
<td>0.65 (0.26 – 1.63)</td>
<td>&gt;1.43&lt;sup&gt;α&lt;/sup&gt;</td>
<td>0.13 (0.12 – 0.13)</td>
</tr>
<tr>
<td>5.2:1 Clomip/Nalbuphine</td>
<td>0.10 (0.08 – 0.12)</td>
<td>0.16 (0.05 – 0.52)</td>
<td>0.84 (0.46 – 1.52)</td>
<td>0.06 * (0.05 – 0.07)</td>
</tr>
<tr>
<td>15.6:1 Clomip/Nalbuphine</td>
<td>0.09 (0.04 – 0.22)</td>
<td>0.23 (0.07 – 0.76)</td>
<td>1.21 (0.53 – 2.77)</td>
<td>0.09 (0.05 – 0.17)</td>
</tr>
<tr>
<td>Morphine Alone</td>
<td>0.74 (0.24 – 2.27)</td>
<td>2.46 (1.53 – 3.97)</td>
<td>&gt;4.27&lt;sup&gt;α&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>0.53:1 Clomip/Morphine</td>
<td>0.73 (0.58 – 0.91)</td>
<td>1.42 (0.85 – 2.38)</td>
<td>&gt;3.81&lt;sup&gt;α&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>1.6:1 Clomip/Morphine</td>
<td>0.54 (0.40 – 0.75)</td>
<td>1.31 (0.56 – 3.06)</td>
<td>3.39 (2.66 – 4.31)</td>
<td></td>
</tr>
<tr>
<td>4.8:1 Clomip/Morphine</td>
<td>0.59</td>
<td>2.16</td>
<td>3.59</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Clomip/Morphine</td>
<td>Methadone Alone</td>
<td>Clomip/Methadone</td>
<td></td>
</tr>
<tr>
<td>----------------</td>
<td>----------------</td>
<td>-----------------</td>
<td>-----------------</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(0.40 – 0.86)</td>
<td>(1.21 – 3.88)</td>
<td>(2.51 – 5.13)</td>
<td></td>
</tr>
<tr>
<td>Methadone Alone</td>
<td>1.17 (0.42 – 3.21)</td>
<td>2.83 (1.60 – 5.01)</td>
<td>4.02 (2.87 – 5.63)</td>
<td></td>
</tr>
<tr>
<td>0.33:1 Clomip/Methadone</td>
<td>0.75 (0.35 – 1.59)</td>
<td>1.72 (0.75 – 3.95)</td>
<td>3.73 (3.05 – 4.57)</td>
<td></td>
</tr>
<tr>
<td>1:1 Clomip/Methadone</td>
<td>0.71 (0.28 – 1.82)</td>
<td>2.37 (1.90 – 2.96)</td>
<td>&gt; 4.69B (3.80 – 5.79)</td>
<td></td>
</tr>
<tr>
<td>3:1 Clomip/Methadone</td>
<td>0.56 (0.37 – 0.85)</td>
<td>3.73 (3.08 – 4.52)</td>
<td>&gt; 3.49B (2.42 – 5.03)</td>
<td></td>
</tr>
</tbody>
</table>

A Indicates mean ED50 for three of four monkeys.

B Indicates mean ED50 for two of four monkeys.

* Indicates that 95% confidence intervals do not overlap for nalbuphine in some proportion with clomipramine compared to nalbuphine alone.
Table 2: Effects of clomipramine on the relative potency of nalbuphine, morphine, and methadone to produce rate suppression vs. thermal nociception. Experimentally determined dose ratios were calculated as the potency (ED50) in the assay of schedule-controlled responding (SCR) / potency (ED50) in the assay of thermal nociception at stimulus intensities of 50°C or 54°C or in the assay of capsaicin-induced thermal allodynia.

<table>
<thead>
<tr>
<th>Treatment Condition</th>
<th>SCR/50°C</th>
<th>SCR/54°C</th>
<th>SCR/Thermal Allodynia</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nalbuphine Alone</td>
<td>0.26</td>
<td>Not calculable</td>
<td>1.44</td>
</tr>
<tr>
<td>1.7:1 Clomip/Nalbuphine</td>
<td>0.15 *</td>
<td>Not calculable</td>
<td>0.77</td>
</tr>
<tr>
<td>5.2:1 Clomip/Nalbuphine</td>
<td>0.63</td>
<td>0.12 *</td>
<td>1.67</td>
</tr>
<tr>
<td>15.6:1 Clomip/Nalbuphine</td>
<td>0.39</td>
<td>0.07 *</td>
<td>1.00</td>
</tr>
<tr>
<td>Morphine Alone</td>
<td>0.30</td>
<td>Not calculable</td>
<td></td>
</tr>
<tr>
<td>0.53:1 Clomip/Morphine</td>
<td>0.51</td>
<td>Not calculable</td>
<td></td>
</tr>
<tr>
<td>1.6:1 Clomip/Morphine</td>
<td>0.41</td>
<td>0.16 *</td>
<td></td>
</tr>
<tr>
<td>4.8:1 Clomip/Morphine</td>
<td>0.27 *</td>
<td>0.16 *</td>
<td></td>
</tr>
<tr>
<td>Methadone Alone</td>
<td>0.41</td>
<td>0.29</td>
<td></td>
</tr>
<tr>
<td>Ratio</td>
<td>Clomip/Methadone</td>
<td>Value 1</td>
<td>Value 2</td>
</tr>
<tr>
<td>-------</td>
<td>-----------------</td>
<td>---------</td>
<td>---------</td>
</tr>
<tr>
<td>0.33:1</td>
<td>Clomip/Methadone</td>
<td>0.44</td>
<td>0.20 *</td>
</tr>
<tr>
<td>1:1</td>
<td>Clomip/Methadone</td>
<td>0.30 *</td>
<td>Not calculable</td>
</tr>
<tr>
<td>3:1</td>
<td>Clomip/Methadone</td>
<td>0.15 *</td>
<td>Not calculable</td>
</tr>
</tbody>
</table>

* Asterisk indicates that 95% confidence limits do not overlap between the assay of schedule controlled responding and the assay of thermal nociception at that thermal intensity.
Figure 1
Figure 3

- Nalbuphine Alone
- 1.7:1 Clomip/Nalbu
- 5.2:1 Clomip/Nalbu
- 15.6:1 Clomip/Nalbu

% MPE

Dose Nalbuphine (mg/kg)
Figure 4